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Performance data of screening mammography at a dedicated 
breast health centre
J P Apffelstaedt, V Steenkamp, K Baatjes
In Western societies, mammographic screening is part of 
routine health care and has been instrumental in reducing the 
mortality of this dreaded disease.1 An editorial by Dent and 
Panieri 2 reflected on screening mammography and elicited 
lively debate. In our opinion, they missed the point, as it was 
based on a re-assessment of data gathered over 20 years ago 
with obsolete technology – data that had been gathered in 
populations that might have had markedly different prevalence 
and incidence patterns from South African populations. 
Furthermore, the background of a resource-restricted country 
has an influence on the interpretation of screening data. A 
database search yielded not a single publication detailing 
results of screening mammography in Africa, indicating a 
crucial lack of data for this important health care topic from 
the continent. Cognisant of these limitations, we present a first 
analysis of screening mammography in a dedicated breast 
health centre in Africa, establishing a performance benchmark 
and providing data to expedite health care policy and funding 
decisions.
Methods
All mammograms performed between January 2003 and 
August 2008 at a dedicated breast centre were entered into 
a prospective database, with permission of the patients. 
Mammography was performed exclusively by certified 
mammographers on state-of-the-art equipment, initially 
film-screen and, from July 2006, full-field digital equipment 
(GE Healthcare, Chalfont St Giles, UK). Double reading by 
experienced readers was performed with consensus after the 
second reading. Readers were practising clinicians with a 
special interest in breast health, or certified mammographers 
who had completed an internationally recognised course 
in mammography interpretation, had read at least 2 000 
mammograms annually, and had a minimum of 50 hours 
annually of continued professional development in clinico-
pathological and imaging correlation in breast health.
Data recorded were: age and gender, indications for 
mammography and outcomes. Indications for screening 
mammography as published by the American Cancer Society3 
were adhered to. Outcomes were classified in a simplified 
classification system based on the Breast Imaging Reporting 
and Data System (BIRADS).4 BIRADS categories 3 and 4 were 
combined as indeterminate; patients with these lesions were 
either asked to return for further imaging examinations and 
a short-term follow-up examination, or a tissue sample was 
obtained for pathological examination. Patients not returning 
for follow-up examination were contacted telephonically 
to ensure compliance. All lesions categorised as BIRADS 5 
underwent tissue acquisition for histopathological testing.
Data were entered into and analysed with a commercially 
available software package (MS Office XP Pro, Microsoft 
Corporation, Washington, USA).
Results
The number of mammograms and their outcome is shown in 
Table I.
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Background. Mammographic screening has become part of 
routine health care. We present a first analysis of screening 
mammography in a dedicated breast health centre in Africa.
Objective. To establish a performance benchmark and provide 
data for health care policy and funding decisions on screening 
mammography.
Method. All mammography performed between January 2003 
and August 2008 was entered into a prospective database. 
Mammography was performed exclusively by certified 
mammographers and double-read by experienced readers.
Results. Outcomes were classified in a simplified classification 
system based on the Breast Imaging Reporting and Data 
System (BIRADS). In 40 - 49-year-old women,  
3 192 mammograms led to a recall rate of 4.7%, a biopsy 
rate of 1.9% and a cancer diagnosis rate of 3.8 per 1 000 
examinations; for women of 50 years and older, the 
corresponding figures were 4 446, 5.4%, 2.6% and 9.7 per 
1 000. Of the cancers detected, 31% were in situ and, of the 
invasive cancers, 81% were node-negative. These figures were 
established by a dedicated surgeon-led team and fall within 
the range expected in organised screening programmes in 
resource-rich environments, providing a first benchmark for 
screening mammography in Africa.
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The analysis of screening performance indicators is shown in 
Table II.
Discussion
Breast cancer screening in women is well researched, with 
well-known early studies and later in-service experience 
establishing the benefits of mammographic screening in 
defined populations.1 As a result, performance benchmarks 
have been established; any screening should adhere to these 
to minimise the harm resulting from increased anxiety, false-
positive results and increased cost.5,6 If benchmarking for 
screening is undertaken, the prevalence and incidence of the 
screened condition in the population should ideally be known; 
however, in many resource-limited countries, this is not the 
case. In South Africa, the accuracy of figures in the National 
Cancer Registry reports for different population groups has 
been questioned. Available data indicate that the breast cancer 
incidence in whites is comparable with that of England; in 
other population groups, the incidence is much lower but 
still comparable with other countries that have instituted a 
population screening programme, such as Singapore7 (except 
for black population groups). Applying the National Cancer 
Registry data is problematic as they do not stratify for socio-
economic factors, and racial classification may be construed 
as offensive and may not measure what it is intended to.8 In 
patients who present for screening, socio-economic factors 
may play a more important role than race and ethnicity. Socio-
economic status as expressed by voluntary participants in 
screening correlates well with breast cancer risk.9
The availability of the service attracts individuals who 
wish to be screened. Consequently, most examinations at our 
centre are screening examinations. In opportunistic screening, 
less emphasis is placed on quality controls than on organised 
screening programmes.10
A decade-long effort to improve the mammographic quality 
in Michigan11 illustrates that, even in a litigious environment 
like the USA, the mere presence of a mammographic service 
does not guarantee quality levels sufficient for effective 
screening. Consequently, complex mechanisms have 
been established to ensure mammographic quality in the 
USA,12 the European Union13 and Australia.14 In a resource-
restricted environment such as South Africa, it is unrealistic 
to contemplate the establishment and maintenance of such 
complex components of societal infrastructure. A simplified 
system of quality control would be more appropriate to ensure 
that scarce resources are employed effectively and based on 
the principal outcome measures of efficacy and safety. Table 
III details these outcome measures and how the present series 
compares with international standards.
The caseload/quality relationship is well documented in 
mammography, with specialised readers with caseloads of 
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Table II. Analysis of screening performance indicators
      N    Per 1 000 examinations
Total of cancers diagnosed    55     7.2
Cancers in 40 - 49 years age group   12     3.8
Cancers in ≥50 years age group   43     9.7
In situ cancers     17     31%
Invasive cancers     38     69%
Invasive cancers, maximum diameter*      Percentage of screen-detected invasive cancers
   <5 mm        4     13%
   6 - 10 mm       9     28%
   11 - 20 mm     14     44%
   >20 mm       5     16%
Node-negative     26     81%
Node-positive       6     19%
*Six patients were censored: 2 had neoadjuvant therapy, 3 had not completed treatment, and in 1 the final pathology was not accessible.
The average diameter of invasive tumours was 12 mm.
Table I. Number of mammograms and their outcome
             Further workup
             recommended:       Biopsies: N  
            Screening         N (% of screening      (% of screening  Cancers: N
Total             mammograms       mammograms  (% of biopsies
mammograms         Total  N per age group        per age group)       per age group)  performed)
10 499          7 638 3 192 (40 - 49 years)        152 (4.7%)       61 (1.9%)  12 (20%)  
    4 446 (≥50 years)*        238 (5.4%)       116 (2.6%)  43 (37%) 
*Includes 263 women ≥70 years of age.
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more than 2 000 mammograms per year working in dedicated 
breast units, detecting more cancers and generating less false-
positives than general readers.
Africa, in common with much of the developing world, 
has a lamentable shortage of radiologists and educational 
resources, specifically in mammography.19 Evidence from 
large series examining the interpretation of mammograms 
by radiographers in Canada, the Netherlands and England 
indicates that radiographers in screening programmes can read 
mammograms ‘at least as well as’ radiologists. Surgeons also 
can read mammograms as accurately as radiologists.20 This is 
further supported by data on interventional diagnostics which 
demand an accurate understanding of breast imaging; in the 
USA, about a quarter of all stereotactic biopsies are performed 
by surgeons, and surgeons perform ultrasound-guided biopsies 
with results comparable to those of radiologists.21-25 Indeed, 
performance of these interventions by surgeons was found to 
be less inconvenient and more cost-effective.23 In Germany, 
gynaecologists and radiologists read mammograms. For the 
series that we analysed, mammography reading was conducted 
entirely by surgeons and mammographers dedicated to breast 
health management. The results achieved not only compare 
favourably with those achieved in community screening 
series worldwide,26 but also are similar to results achieved in 
high-quality organised screening programmes in resource-
rich environments, and are within ‘the desirable range 
recommended for highly skilled radiologists’ in the USA.5 
While this in itself does not confirm the cost-effectiveness of 
mammographic screening in a resource-restricted environment, 
it indicates that, in the community screened in this series, 
cancer detection rates are well within the rage of environments 
where mammographic screening is a recognised health 
intervention. It further confirms the importance of dedication 
to breast health and stringent quality control at all levels of 
the diagnostic process in the achievement of good outcomes 
in breast cancer screening over professional qualifications of 
the professionals involved. We hope that other professionals 
in the screening arena in South Africa will join us in our quest 
to provide breast health services of the highest quality to the 
women of our country. A crucial step in this is to publish 
screening performance data, as given above, to establish the 
effectiveness of their service to the public, funders and health 
authorities. Mammographic screening should be restricted 
to institutions that provide evidence of effective screening to 
ensure optimal application of scarce resources.
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Table III. Outcome measures and how the present series compares with international standards
Criterion      USA5                  UK (NHS)15,16  Australia17           Singapore18                   Present series
Recall rate     9.8%  4.6%    4.2 - 9.8%   -        4.7 - 5.4%
Biopsy rate       -  50 - 70 yr: 1.78%     -    -        1.9 - 2.6%
Malignancy     33.8%  44.8%      -            43%        20 - 37%
rate of biopsies
Cancers per 1 000      4.7 all      -    5.6            4.8 all        3.8
examinations 40 -      examinations                examinations
49 years old 
Cancers per 1 000   8.0    5.6           9.7
examinations 50 - 
69 years old
Percentage of      21.6%  21.9%    20.2%             25%        31%
in situ cancers
Percentage of      78.4%  78.1%    79.8%             75%        69%
invasive cancers
Invasive cancers
   <5 mm      10%*  25%    63% (tumours             29%        13%
        <15 mm)
   6 - 10 mm     27%*                28%
   11 - 20 mm     32%*  48%    37% (tumours 	 												71%        44%
   >20 mm     21%*  27%    ≥15 mm)           16%
Percentage of      79.8%  76%       -             65%        81%
node-negative
cancers
Percentage of     20.2%  24%       -             35%        19%
node-positive
cancers
* In 8.5% of invasive cancers, the size was unknown.
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